Source : INDIA TODAY NEWS
A novel drug designed to prevent muscle loss has shown remarkable early results in clinical trials, offering hope to patients increasingly using GLP-1-based therapies for weight management and diabetes.
Apitegromab, a myostatin inhibitor, was able to reduce muscle loss by more than 50 percent compared to placebo when administered alongside tirzepatide (Mounjaro), according to research published in Nature Medicine.
A myostatic inhibitor is a class of medicines that block the effect of myostatic, a naturally occurring protein that limits skeletal muscle growth and helps to treat muscle-wasting conditions.
advertisement
Leading endocrinologist Dr Ambrish Mithal said, “These are early days but amazing results – potentially a game changer.”
GLP-1 receptor agonists such as tirzepatide and semaglutide have seen rapid adoption in India, gaining widespread popularity within a year of their launch due to their proven efficacy in weight reduction and glycaemic control.
Tirzepatide was launched by Eli Lilly under the brand name Mounjaro. Semaglutide by Novo Nordisk also hit the Indian market under the brand names Wegovy and Ozempic and after its patent expired in March this year, over 30 generic versions of the drug have flooded the Indian pharma market.
However, one concern has been that intensive weight-loss therapy may also lead to unintended muscle loss, potentially undermining metabolic health.
A NEW FRONTIER
Apitegromab works by targeting myostatin, a protein that inhibits muscle growth. By blocking myostatin, the drug promotes muscle preservation even in the context of significant weight loss induced by GLP-1 based therapy.
In the study, participants receiving the combination of apitegromab and tirzepatide experienced over 50% less muscle loss compared to those on tirzepatide alone, highlighting the potential for synergistic therapy.
Researchers are particularly optimistic that this dual approach could transform care for people with obesity or type 2 diabetes who are at risk of sarcopenia, the age-related decline in muscle mass.
Dr Mithal emphasized that maintaining lean muscle is crucial not only for physical strength but also for metabolic health, insulin sensitivity, and long-term mobility.
GLP-1 BOOM AND MUSCLE CHALLENGE
The rise of GLP-1 receptor agonists has been meteoric. Drugs like tirzepatide and semaglutide have become household names in India within just a year of launch, thanks to aggressive marketing and compelling clinical evidence for rapid, sustained weight loss.
While highly effective, these therapies are not without side effects. One of the emerging challenges is the unintended reduction of muscle mass during significant fat loss, which can affect energy levels, metabolic rate, and overall health.
The introduction of apitegromab could address this concern. According to the Nature Medicine study, the drug was generally well-tolerated, and participants showed improvements not only in muscle mass retention but also in functional strength measures, such as grip strength and walking speed.
FUTURE DIRECTIONS AND REGULATORY OUTLOOK
Although the results are promising, researchers caution that these are early-stage findings. Larger, long-term trials are required to confirm safety and efficacy, and regulatory approval will be a key hurdle before Apitegromab becomes widely available.
“While this is a very exciting development, we need to see data over longer periods and in more diverse populations,” said a Bengaluru-based metabolic disease specialist.
“If the findings hold, this could be a major advancement in managing weight loss without sacrificing muscle health,” she added.
Experts also note the potential for broader applications, including in age-related sarcopenia and chronic illnesses that lead to muscle wasting. If successful, apitegromab could be the first in a new class of therapies that complement existing GLP-1 medicines, offering patients a more balanced approach to weight and metabolic management.
– Ends
SOURCE :- TIMES OF INDIA
